Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'No Future Without New Drugs': Yuhan CSO On Open Innovation Strategy

TPD, RNA, Cell/Gene Therapies All In Sights

Executive Summary

Yuhan’s chief scientific officer shares why the leading Korean pharma firm is stepping up its open innovation activities and how this is helping to transform the company into a more global and R&D-based enterprise.

You may also be interested in...



Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab

Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.

Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns

Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.

Orange Grove CEO: Korean Opportunities A Priority In Global Expansion

US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel